stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) EBITDA
Natera, Inc.'s EBITDA for fiscal 2025 was −$266.4M, compared with −$191.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$223.9M. Over the past ten years it has ranged from −$518.2M (fiscal 2022) to −$54.0M (fiscal 2015); the current reading is higher than 36% of that period. Natera, Inc. ranks 47th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$266.4M | — |
| FY2024 | −$191.0M | — |
| FY2023 | −$419.8M | — |
| FY2022 | −$518.2M | — |
| FY2021 | −$447.9M | — |
| FY2020 | −$201.8M | — |
| FY2019 | −$107.2M | — |
| FY2018 | −$106.5M | — |
| FY2017 | −$127.2M | — |
| FY2016 | −$93.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$54.6M | — |
| Mar 2026 | −$73.3M | — |
| Dec 2025 | −$8.7M | — |
| Sep 2025 | −$87.3M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.5B |
| DGX Quest Diagnostics Incorporated compare | $2.3B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.7B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement